Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCX4430 · 1 trial · 2 indications
Evaluation of the incidence and severity of adverse events, laboratory abnormalities, ECG findings, vital sign changes, injection site and physical examination findings
| Arm | Type | Description |
|---|---|---|
| BCX4430 | EXPERIMENTAL | BCX4430 administered as an IM injection |
| Placebo | PLACEBO_COMPARATOR | Matched placebo administered as an IM injection |
| Name | Type | Description |
|---|---|---|
| BCX4430 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Weight ≥ 50 kg (110 lbs) and ≤ 100 kg (220 lbs) 2. Body mass index (BMI) of 19-32 kg/m2 3. Willing to abstain from alcohol consumption for a period of 2 days prior to and during the study 4. Sexually active women of child bearing potential and sexually active men must utilize...
BCX4430 is an investigational small molecule being developed for the treatment of filovirus infections, including Ebola virus infection. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BCX4430 is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BCRX.
BCX4430 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. Its Phase 1 trial has been completed.
BCX4430 has been studied in one completed Phase 1 clinical trial, identified as NCT02319772. This trial evaluated the safety, tolerability, and pharmacokinetics of BCX4430 in 94 healthy volunteers in the United Kingdom.
BCX4430 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established for the treatment of filovirus infections.